Theranostic applications of CXCR4-targeted imaging ligands in lymphoma: integrating diagnosis and precision therapy - PubMed
6 hours ago
- #theranostics
- #lymphoma
- #CXCR4
- CXCR4 is a G protein-coupled receptor involved in immune regulation, tumor progression, and therapy resistance.
- Overexpression of CXCR4 in lymphoma promotes malignant cell survival and correlates with poor prognosis.
- CXCR4-targeted imaging ligands include peptide-based radiotracers (e.g., 68Ga-Pentixafor) and small molecules (e.g., [64Cu]AMD3100) for PET and SPECT imaging.
- Therapeutic strategies include peptide antagonists, radioligand therapies, small-molecule inhibitors, and monoclonal antibodies.
- Challenges include off-target uptake due to physiological CXCR4 expression and compensatory signaling via CXCR7.
- Future directions involve dual-receptor targeting, nanoparticle-based delivery, and integration into precision oncology.